natgillin/translations-raw huggingface dataset:
the relevance of the metabolites that may occur in groundwater, taking into account any relevant classification for pethoxamid in accordance with Regulation (EC) No 1272/2008 of the Parliament and of the Council, in particular as carcinogen category 2;
relevantnosti metabolita koji mogu biti prisutni u podzemnim vodama, uzimajući u obzir relevantno razvrstavanje petoksamida u skladu s Uredbom (EZ) br. 1272/2008 Europskog parlamenta i Vijeća, osobito kao karcinogene tvari kategorije 2.;
the effect of water treatment processes on the nature of residues present in drinking water;
učinku postupaka pročišćavanja vode na vrstu ostataka prisutnih u vodi za piće;
the endocrine disrupting potential of pethoxamid as regards the thyroid modality/pathway as a minimum providing mechanistic data to clarify whether there is a thyroid endocrine disrupting mode of action.
potencijalu petoksamida kao endokrinog disruptora rada štitnjače i dostaviti barem podatke o mehanizmu djelovanja kako bi se razjasnilo postoji li endokrino disruptivno djelovanje na rad štitnjače.
The applicant shall submit the information requested under point 1 within one year after the publication of the opinion adopted by the Committee for Risk Assessment of the European Chemicals Agency in accordance with Article 37(4) Regulation (EC) No 1272/2008 of the European Parliament and of the Council with respect to pethoxamid and the information requested.
Podnositelj zahtjeva mora dostaviti informacije iz točke 1. u roku od jedne godine od objave mišljenja o riziku i zatraženim informacijama Odbora za procjenu rizika Europske agencije za kemikalije (ECHA) donesenog u skladu s člankom 37. stavkom 4. Uredbe (EZ) br. 1272/2008 Europskog parlamenta i Vijeća.
The applicant shall submit the information requested under point 2 within two years of a guidance document on evaluation of the effect of water treatment processes on the nature of residues present in surface and groundwater being made public by the Commission.
Podnositelj zahtjeva mora dostaviti informacije iz točke 2. u roku od dvije godine nakon što Komisija objavi smjernice za ocjenu učinka postupaka pročišćavanja vode na vrstu ostataka prisutnih u površinskim i podzemnim vodama.
The applicant shall submit the information requested under point 3 by 10 November 2020 in accordance with Commission Regulation (EU) 2018/605 amending Annex II to Regulation (EC) No 1107/2009 by setting out scientific criteria for the determination of endocrine disrupting properties and the joint guidance document to identify endocrine disrupting substances as adopted by EFSA and ECHA.
Podnositelj zahtjeva mora dostaviti informacije iz točke 3. do 10. studenoga 2020. u skladu s Uredbom Komisije (EU) 2018/605 o izmjeni Priloga II. Uredbi (EZ) br. 1107/2009 utvrđivanjem znanstvenih kriterija za određivanje svojstava endokrine disrupcije i sa zajedničkim smjernicama za utvrđivanje endokrino disruptivnih tvari koje su donijele EFSA i ECHA.
Commission Regulation (EU) 2018/605 of 19 April 2018 amending Annex II to Regulation (EC) No 1107/2009 by setting out scientific criteria for the determination of endocrine disrupting properties (OJ L 101, 20.4.2018, p. 33).
Uredba Komisije (EU) 2018/605 оd 19. travnja 2018. o izmjeni Priloga II. Uredbi (EZ) br. 1107/2009 utvrđivanjem znanstvenih kriterija za određivanje svojstava endokrine disrupcije (SL L 101, 20.4.2018., str. 33.).
in Part A, entry 122 on pethoxamid is deleted;
u dijelu A briše se unos 122. za petoksamid;
The applicant shall submit the information requested under point 3 by 10 November 2020 in accordance with Commission Regulation (EU) 2018/605 amending Annex II to Regulation (EC) No 1107/2009 by setting out scientific criteria for the determination of endocrine disrupting properties and the joint guidance document to identify endocrine disrupting substances as adopted by EFSA and ECHA.’
Podnositelj zahtjeva mora dostaviti informacije iz točke 3. do 10. studenoga 2020. u skladu s Uredbom Komisije (EU) 2018/605 o izmjeni Priloga II. Uredbi (EZ) br. 1107/2009 utvrđivanjem znanstvenih kriterija za određivanje svojstava endokrine disrupcije i sa zajedničkim smjernicama za utvrđivanje endokrino disruptivnih tvari koje su donijele EFSA i ECHA.”
Commission Implementing Regulation (EU) 2018/1265
Provedbena uredba Komisije (EU) 2018/1265
approving the active substance fenpicoxamid in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending Commission Implementing Regulation (EU) No 540/2011
o odobravanju aktivne tvari fenpikoksamid u skladu s Uredbom (EZ) br. 1107/2009 Europskog parlamenta i Vijeća o stavljanju na tržište sredstava za zaštitu bilja te o izmjeni Provedbene uredbe Komisije (EU) br. 540/2011
In accordance with Article 7(1) of Regulation (EC) No 1107/2009 the United Kingdom received on 2 December 2014 an application from Dow AgroScience GmbH for the approval of the active substance fenpicoxamid.
U skladu s člankom 7. stavkom 1. Uredbe (EZ) br. 1107/2009 Ujedinjena Kraljevina je 2. prosinca 2014. od trgovačkog društva Dow AgroScience GmbH primila zahtjev za odobrenje aktivne tvari fenpikoksamid.
In accordance with Article 9(3) of that Regulation, the United Kingdom, as rapporteur Member State, notified the applicant, the other Member States, the Commission and the European Food Safety Authority (‘the Authority’) on 13 January 2015 of the admissibility of the application.
U skladu s člankom 9. stavkom 3. te uredbe Ujedinjena Kraljevina je kao država članica izvjestiteljica 13. siječnja 2015. obavijestila podnositelja zahtjeva, ostale države članice, Komisiju i Europsku agenciju za sigurnost hrane („Agencija”) o prihvatljivosti zahtjeva.
On 13 October 2016 the rapporteur Member State submitted a draft assessment report to the Commission with a copy to the Authority, assessing whether that active substance can be expected to meet the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009.
Država članica izvjestiteljica dostavila je 13. listopada 2016. nacrt izvještaja o procjeni Komisiji, pri čemu je primjerak poslala Agenciji, u kojem ocjenjuje može li se očekivati da ta aktivna tvar ispunjava mjerila za odobravanje iz članka 4. Uredbe (EZ) br. 1107/2009.
The assessment of the additional information by the rapporteur Member State was submitted to the Authority in the format of an updated draft assessment report on 31 July 2017.
Država članica izvjestiteljica dostavila je Agenciji ocjenu dodatnih informacija 31. srpnja 2017. u obliku ažuriranog nacrta izvješća o ocjeni.
On 22 December 2017 the Authority communicated to the applicant, the Member States and the Commission its conclusion on whether the active substance fenpicoxamid can be expected to meet the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009.
Agencija je 22. prosinca 2017. podnositelju zahtjeva, državama članicama i Komisiji dostavila svoj zaključak o tome može li se za aktivnu tvar fenpikoksamid očekivati da ispunjava mjerila za odobravanje iz članka 4. Uredbe (EZ) br. 1107/2009.
On 23 March 2018 the Commission presented to the Standing Committee on Plants, Animals, Food and Feed the review report for fenpicoxamid and a draft Regulation providing that fenpicoxamid is approved.
Komisija je 23. ožujka 2018. Stalnom odboru za bilje, životinje, hranu i hranu za životinje predstavila izvješće o pregledu za fenpikoksamid i nacrt uredbe kojom se predviđa odobrenje fenpikoksamida.
It has been established with respect to one or more representative uses of at least one plant protection product containing the active substance, and in particular the uses which were examined and detailed in the review report, that the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009 are satisfied.
Za jednu ili više reprezentativnih uporaba najmanje jednog sredstva za zaštitu bilja koje sadržava tu aktivnu tvar, a posebno u pogledu uporaba koje su ispitane i navedene u izvješću o pregledu, utvrđeno je da su mjerila za odobravanje iz članka 4. Uredbe (EZ) br. 1107/2009 ispunjena.
It is therefore appropriate to approve fenpicoxamid.
Stoga je primjereno odobriti fenpikoksamid.
The active substance fenpicoxamid, as specified in Annex I, is approved subject to the conditions laid down in that Annex.
Aktivna tvar fenpikoksamid, kako je navedena u Prilogu I., odobrava se u skladu s uvjetima utvrđenima u tom prilogu.
EFSA Journal 2018;16(1):5146, 27 pp. https://doi.org/10.2903/j.efsa.2018.5146.
EFSA Journal 2018.;16(1):5146, 27 str. https://doi.org/10.2903/j.efsa.2018.5146.
Fenpicoxamid
Fenpikoksamid
CAS No: 517875-34-2
CAS br.: 517875-34-2
CIPAC No: 991
CIPAC br.: 991
(3S,6S,7R,8R)-8-benzyl-3-3-[(isobutyryloxy)methoxy]-4-methoxypyridine-2-carboxamido-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate
(3S,6S,7R,8R)-8-benzil-3-3-[(izobutiriloksi)metoksi]-4-metoksipiridin-2-karboksamido-6-metil-4,9-diokso-1,5-dioksonan-7-il izobutirat
11 October 2028
11. listopada 2028.
For the implementation of the uniform principles as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the review report on fenpicoxamid, and in particular Appendices I and II thereto, shall be taken into account.
Za provedbu jedinstvenih načela iz članka 29. stavka 6. Uredbe (EZ) br. 1107/2009 moraju se uzeti u obzir zaključci izvješća o pregledu za fenpikoksamid, a posebno njegovi dodaci I. i II.
the impact of processing on the consumer risk assessment,
utjecaj prerade na procjenu rizika za potrošače,
the technical specification of the active substance as manufactured (based on commercial scale production) and the compliance of the toxicity batches with the confirmed technical specification;
tehnička specifikacija aktivne tvari kako se proizvodi (na temelju komercijalne razine proizvodnje) i sukladnost serija toksičnosti s potvrđenom tehničkom specifikacijom;
the effect of water treatment processes on the nature of residues present in drinking water;
učinak postupaka pročišćavanja vode na vrstu ostataka prisutnih u vodi za piće;
the endocrine disrupting potential of fenpicoxamid as regards the thyroid modality/pathway, providing in particular mechanistic data to clarify according to Points 3.6.5 and 3.8.2 of Annex II of Regulation (EC) No 1107/2009, as amended by Commission Regulation (EU) 2018/605, whether the effects observed in the studies submitted for approval are or are not related to a thyroid endocrine disrupting mode of action.
potencijalna endokrina štetnost fenpikoksamida za rad štitnjače, uz posebno pružanje podataka o mehanizmu djelovanja kojima se pojašnjava, u skladu s točkama 3.6.5. i 3.8.2. Priloga II. Uredbi (EZ) br. 1107/2009, kako je izmijenjena Uredbom Komisije (EU) 2018/605, jesu li učinci opaženi u studijama koje su podnesene na odobrenje povezani s endokrinom disrupcijom štitnjače.
The applicant shall submit to the Commission, the Member States and the Authority the information referred to in point 1 by 11 October 2019, in point 2 within 2 years of a guidance document on evaluation of the effect of water treatment processes on the nature of residues present in surface and groundwater being made public by the Commission and in point 3 by 10 November 2020.
Podnositelj zahtjeva dužan je Komisiji, državama članicama i Agenciji dostaviti informacije iz točke 1. do 11. listopada 2019., iz točke 2. u roku od dvije godine nakon što Komisija javnosti učini dostupnima smjernice za ocjenu učinka postupaka pročišćavanja vode na vrstu ostataka prisutnih u površinskim odnosno podzemnim vodama i iz točke 3. do 10. studenoga 2020.
Commission Regulation (EU) 2018/605 of 19 April 2018 amending Annex II to Regulation (EC) No 1107/2009 by setting out scientific criteria for the determination of endocrine disrupting properties (OJ L 101, 20.4.2018, p. 33).
Uredba Komisije (EU) 2018/605 оd 19. travnja 2018. o izmjeni Priloga II. Uredbi (EZ) br. 1107/2009 utvrđivanjem znanstvenih kriterija za određivanje svojstava endokrine disrupcije. (SL L 101, 20.4.2018., str. 33.).
The applicant shall submit to the Commission, the Member States and the Authority the information referred to in point 1 by 11 October 2019, in point 2 within 2 years of a guidance document on evaluation of the effect of water treatment processes on the nature of residues present in surface and groundwater being made public by the Commission and in point 3 by 10 November 2020.’
Podnositelj zahtjeva dužan je Komisiji, državama članicama i Agenciji dostaviti informacije iz točke 1. do 11. listopada 2019., iz točke 2. u roku od dvije godine nakon što Komisija učini dostupnima javnosti smjernice za ocjenu učinka postupaka pročišćavanja vode na vrstu ostataka prisutnih u površinskim odnosno podzemnim vodama i iz točke 3. do 10. studenoga 2020.”
Commission Regulation (EU) 2018/605 of 19 April 2018 amending Annex II to Regulation (EC) No 1107/2009 by setting out scientific criteria for the determination of endocrine disrupting properties.
Uredba Komisije (EU) 2018/605 оd 19. travnja 2018. o izmjeni Priloga II. Uredbi (EZ) br. 1107/2009 utvrđivanjem znanstvenih kriterija za određivanje svojstava endokrine disrupcije.
(OJ L 101, 20.4.2018, p. 33).
(SL L 101, 20.4.2018., str. 33.).
Conclusion on the peer review of the pesticide risk assessment of the active substance fenpicoxamid (XDE-777).
Zaključak o stručnom pregledu procjene rizika od uporabe aktivne tvari fenpikoksamid (XDE-777) kao pesticida.
Commission Implementing Regulation (EU) 2018/1266
Provedbena uredba Komisije (EU) 2018/1266
amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances 1-decanol, 6-benzyladenine, aluminium sulfate, azadirachtin, bupirimate, carboxin, clethodim, cycloxydim, dazomet, diclofop, dithianon, dodine, fenazaquin, fluometuron, flutriafol, hexythiazox, hymexazol, indolylbutyric acid, isoxaben, lime sulphur, metaldehyde, paclobutrazol, pencycuron, sintofen, tau-fluvalinate and tebufenozide
o izmjeni Provedbene uredbe (EU) br. 540/2011 u pogledu produljenja roka važenja odobrenja aktivnih tvari 1-dekanol, 6-benziladenin, aluminijev sulfat, azadiraktin, bupirimat, karboksin, kletodim, cikloksidim, dazomet, diklofop, ditianon, dodin, fenazakin, fluometuron, flutriafol, heksitiazoks, himeksazol, indolilbutanska kiselina, izoksaben, sumporno vapno, metaldehid, paklobutrazol, pencikuron, sintofen, tau-fluvalinat i tebufenozid
Applications for the renewal of the approval of 1-decanol, 6-benzyladenine, aluminium sulfate, azadirachtin, bupirimate, carboxin, clethodim, cycloxydim, dazomet, diclofop, dithianon, dodine, fenazaquin, fluometuron, flutriafol, hexythiazox, hymexazol, indolylbutyric acid, isoxaben, lime sulphur, metaldehyde, paclobutrazol, pencycuron, sintofen, tau-fluvalinate and tebufenozide were submitted in accordance with Commission Implementing Regulation (EU) No 844/2012.
Zahtjevi za produljenje odobrenja tvari 1-dekanol, 6-benziladenin, aluminijev sulfat, azadiraktin, bupirimat, karboksin, kletodim, cikloksidim, dazomet, diklofop, ditianon, dodin, fenazakin, fluometuron, flutriafol, heksitiazoks, himeksazol, indolilbutanska kiselina, izoksaben, sumporno vapno, metaldehid, paklobutrazol, pencikuron, sintofen, tau-fluvalinat i tebufenozid podneseni su u skladu s Provedbenom uredbom Komisije (EU) br. 844/2012.
However, the approval of those substances is likely to expire for reasons beyond the control of the applicant before a decision has been taken on the renewal of their approval.
Međutim, zbog razloga koji su izvan kontrole podnositelja zahtjeva, odobrenja tih tvari vjerojatno će isteći prije donošenja odluke o njihovu produljenju.
In view of the time and resources necessary for completing the assessment of applications for renewal of approval of a large number of active substances the approvals of which are expiring between 2019 and 2021, Commission Implementing Decision C(2016) 6104 established a work programme grouping together similar active substances and setting priorities on the basis of safety concerns for human and animal health or the environment as provided for in Article 18 of Regulation (EC) No 1107/2009.
S obzirom na vrijeme i sredstva koji su potrebni za dovršenje procjene zahtjeva za produljenje odobrenja velikog broja aktivnih tvari za koje odobrenja istječu između 2019. i 2021., Provedbenom odlukom Komisije C(2016)6104 utvrđen je program rada u kojemu se grupiraju slične aktivne tvari i određuju prioriteti na temelju pitanjâ sigurnosti za zdravlje ljudi i životinja ili za okoliš, kako je predviđeno člankom 18. Uredbe (EZ) br. 1107/2009.
As the active substances 1-decanol, 6-benzyladenine, aluminium sulfate, azadirachtin, bupirimate, carboxin, clethodim, cycloxydim, dazomet, diclofop, dithianon, dodine, fenazaquin, fluometuron, flutriafol, hexythiazox, hymexazol, indolylbutyric acid, isoxaben, lime sulphur, metaldehyde, paclobutrazol, pencycuron, sintofen, tau-fluvalinate and tebufenozide do not fall in the prioritised categories of Implementing Decision C(2016) 6104, their approval period should be extended by either two or three years, taking into account the current date of expiry, the fact that in accordance with Article 6(3) of Implementing Regulation (EU) No 844/2012 the supplementary dossier for an active substance is to be submitted no later than 30 months before expiry of the approval, the need to ensure a balanced distribution of responsibilities and work among Member States acting as rapporteurs and co-rapporteurs and the available resources necessary for assessment and decision-making.
Budući da aktivne tvari 1-dekanol, 6-benziladenin, aluminijev sulfat, azadiraktin, bupirimat, karboksin, kletodim, cikloksidim, dazomet, diklofop, ditianon, dodin, fenazakin, fluometuron, flutriafol, heksitiazoks, himeksazol, indolilbutanska kiselina, izoksaben, sumporno vapno, metaldehid, paklobutrazol, pencikuron, sintofen, tau-fluvalinat i tebufenozidnisu nisu obuhvaćene prioritetnim kategorijama u Provedbenoj odluci C(2016)6104, rok važenja odobrenja za te tvari trebalo bi produljiti za dvije ili tri godine, uzimajući u obzir sadašnji datum isteka odobrenja, činjenicu da se u skladu s člankom 6. stavkom 3. Provedbene uredbe (EU) br. 844/2012 dopunska dokumentacija za aktivnu tvar dostavlja najkasnije 30 mjeseci prije isteka odobrenja, potrebu da se osigura ujednačena raspodjela odgovornosti i rada među državama članicama koje djeluju kao izvjestiteljice i suizvjestiteljice te raspoložive resurse potrebne za procjenu i donošenje odluke.
It is therefore appropriate to extend the approval period for the active substances carboxin, clethodim, cycloxydim, dazomet, diclofop, fenazaquin, hymexazol, indolylbutyric acid, metaldehyde, and paclobutrazol by two years, and the approval period of the active substances 1-decanol, 6-benzyladenine, aluminium sulfate, azadirachtin, bupirimate, dithianon, dodine, fluometuron, flutriafol, hexythiazox, isoxaben, lime sulphur, pencycuron, sintofen, tau-fluvalinate and tebufenozide by three years.
Stoga je primjereno produljiti rok važenja odobrenja za aktivne tvari karboksin, kletodim, cikloksidim, dazomet, diklofop, fenazakin, himeksazol, indolilbutansku kiselinu, metaldehid i paklobutrazol za dvije godine, a rok važenja odobrenja za aktivne tvari 1-dekanol, 6-benziladenin, aluminijev sulfat, azadiraktin, bupirimat, ditianon, dodin, fluometuron, flutriafol, heksitiazoks, izoksaben, sumporno vapno, pencikuron, sintofen, tau-fluvalinat i tebufenozid za tri godine.
Where no supplementary dossier in accordance with Implementing Regulation (EU) No 844/2012 is submitted no later than 30 months before the respective expiry date laid down in the Annex to this Regulation, the expiry date should remain the same as before this Regulation or it should be set at the earliest date thereafter.
Ako se dopunska dokumentacija ne dostavi u skladu s Provedbenom uredbom (EU) br. 844/2012 najkasnije 30 mjeseci prije datuma isteka odobrenja utvrđenog u Prilogu ovoj Uredbi, datum isteka odobrenja trebao bi ostati isti kao prije donošenja ove Uredbe ili bi kao datum isteka odobrenja trebalo odrediti najraniji mogući datum nakon tog datuma.
Where the Commission will adopt a Regulation providing that the approval of an active substance referred to in the Annex to this Regulation is not renewed because the approval criteria are not satisfied, the Commission will set the expiry date at the same date as before this Regulation or at the date of the entry into force of the Regulation providing that the approval of the active substance is not renewed, whichever date is later.
Ako Komisija donese uredbu kojom se predviđa da se odobrenje aktivne tvari iz Priloga ovoj Uredbi ne produljuje jer nisu ispunjena mjerila za odobrenje, Komisija kao datum isteka određuje isti datum koji je vrijedio prije donošenja ove Uredbe ili datum stupanja na snagu uredbe kojom se predviđa da se odobrenje aktivne tvari ne produljuje, ovisno o tome koji je datum kasniji.
in the sixth column, expiration of approval, of row 316, Cycloxydim, the date is replaced by ‘31 May 2023’;
u šestom stupcu, prestanak odobrenja, u retku 316., Cikloksidim, datum se zamjenjuje datumom „31. svibnja 2023.”;
in the sixth column, expiration of approval, of row 317, 6-Benzyladenine, the date is replaced by ‘31 May 2024’;
u šestom stupcu, prestanak odobrenja, u retku 317., 6-Benziladenin, datum se zamjenjuje datumom „31. svibnja 2024.”;
in the sixth column, expiration of approval, of row 322, Hymexazol, the date is replaced by ‘31 May 2023’;
u šestom stupcu, prestanak odobrenja, u retku 322., Himeksazol, datum se zamjenjuje datumom „31. svibnja 2023.”;
in the sixth column, expiration of approval, of row 323, Dodine, the date is replaced by ‘31 May 2024’;
u šestom stupcu, prestanak odobrenja, u retku 323., Dodin, datum se zamjenjuje datumom „31. svibnja 2024.”;
in the sixth column, expiration of approval, of row 326, Indolylbutyric acid, the date is replaced by ‘31 May 2023’;
u šestom stupcu, prestanak odobrenja, u retku 326., Indolilbutanska kiselina, datum se zamjenjuje datumom „31. svibnja 2023.”;
in the sixth column, expiration of approval, of row 328, Tau-fluvalinate, the date is replaced by ‘31 May 2024’;
u šestom stupcu, prestanak odobrenja, u retku 328., Tau-fluvalinat, datum se zamjenjuje datumom „31. svibnja 2024.”;
in the sixth column, expiration of approval, of row 329, Clethodim, the date is replaced by ‘31 May 2023’;
u šestom stupcu, prestanak odobrenja, u retku 329., Kletodim, datum se zamjenjuje datumom „31. svibnja 2023.”;
in the sixth column, expiration of approval, of row 330, Bupirimate, the date is replaced by ‘31 May 2024’;
u šestom stupcu, prestanak odobrenja, u retku 330., Bupirimat, datum se zamjenjuje datumom „31. svibnja 2024.”;
in the sixth column, expiration of approval, of row 333, 1-decanol, the date is replaced by ‘31 May 2024’;
u šestom stupcu, prestanak odobrenja, u retku 333., 1-dekanol, datum se zamjenjuje datumom „31. svibnja 2024.”;
in the sixth column, expiration of approval, of row 334, Isoxaben, the date is replaced by ‘31 May 2024’;
u šestom stupcu, prestanak odobrenja, u retku 334., Izoksaben, datum se zamjenjuje datumom „31. svibnja 2024.”;
in the sixth column, expiration of approval, of row 335, Fluometuron, the date is replaced by ‘31 May 2024’;
u šestom stupcu, prestanak odobrenja, u retku 335., Fluometuron, datum se zamjenjuje datumom „31. svibnja 2024.”;
in the sixth column, expiration of approval, of row 337, Carboxin, the date is replaced by ‘31 May 2023’;
u šestom stupcu, prestanak odobrenja, u retku 337., Karboksin, datum se zamjenjuje datumom „31. svibnja 2023.”;
in the sixth column, expiration of approval, of row 339, Dazomet, the date is replaced by ‘31 May 2023’;
u šestom stupcu, prestanak odobrenja, u retku 339., Dazomet, datum se zamjenjuje datumom „31. svibnja 2023.”;
in the sixth column, expiration of approval, of row 340, Metaldehyde, the date is replaced by ‘31 May 2023’;
u šestom stupcu, prestanak odobrenja, u retku 340., Metaldehid, datum se zamjenjuje datumom „31. svibnja 2023.”;
in the sixth column, expiration of approval, of row 341, Sintofen, the date is replaced by ‘31 May 2024’;
u šestom stupcu, prestanak odobrenja, u retku 341., Sintofen, datum se zamjenjuje datumom „31. svibnja 2024.”;